158 related articles for article (PubMed ID: 35103169)
1. Cutaneous Manifestations and Hormonal Changes Among Polycystic Ovary Syndrome Patients at a Tertiary Care Center.
Aljefri YE; Alahmadi RA; Alajmi RS; Alkhamisi TA; Maaddawi HA; Alraddadi AA; Alamri AM
Cureus; 2021 Dec; 13(12):e20593. PubMed ID: 35103169
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China.
Feng JG; Guo Y; Ma LA; Xing J; Sun RF; Zhu W
J Cosmet Dermatol; 2018 Jun; 17(3):511-517. PubMed ID: 28940857
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous manifestation of polycystic ovary syndrome.
Abusailik MA; Muhanna AM; Almuhisen AA; Alhasanat AM; Alshamaseen AM; Bani Mustafa SM; Nawaiseh MB
Dermatol Reports; 2021 Aug; 13(2):8799. PubMed ID: 34659671
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome.
Schmidt TH; Khanijow K; Cedars MI; Huddleston H; Pasch L; Wang ET; Lee J; Zane LT; Shinkai K
JAMA Dermatol; 2016 Apr; 152(4):391-8. PubMed ID: 26720591
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study.
Keen MA; Shah IH; Sheikh G
Indian Dermatol Online J; 2017; 8(2):104-110. PubMed ID: 28405549
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients.
Hong JS; Kwon HH; Park SY; Jung JY; Yoon JY; Min S; Choi YM; Suh DH
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):42-7. PubMed ID: 24628922
[TBL] [Abstract][Full Text] [Related]
7. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne.
Timpatanapong P; Rojanasakul A
J Dermatol; 1997 Apr; 24(4):223-9. PubMed ID: 9164062
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Cutaneous Manifestations With Body Mass Index (BMI) in Polycystic Ovary Syndrome (PCOS) Patients in a Tertiary Care Centre: An Observational Study.
Jena P; Tiwari M; Panda SR; Samantroy S; Panda J
Cureus; 2021 Dec; 13(12):e20695. PubMed ID: 35106232
[TBL] [Abstract][Full Text] [Related]
9. A study on clinical and sonographic features in obese and nonobese patients with polycystic ovary syndrome.
Siddiqui IA; Tamimi W; Tamim H; Aleisa N; Adham M
Arch Gynecol Obstet; 2010 Mar; 281(3):467-71. PubMed ID: 19462174
[TBL] [Abstract][Full Text] [Related]
10. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Skin Changes with Hormonal Changes in Polycystic Ovarian Syndrome: A Cross-sectional Study Clinical Study.
Gowri BV; Chandravathi PL; Sindhu PS; Naidu KS
Indian J Dermatol; 2015; 60(4):419. PubMed ID: 26288423
[TBL] [Abstract][Full Text] [Related]
12. Body mass index and gonadotropin hormones (LH & FSH) associate with clinical symptoms among women with polycystic ovary syndrome.
Esmaeilzadeh S; Andarieh MG; Ghadimi R; Delavar MA
Glob J Health Sci; 2014 Sep; 7(2):101-6. PubMed ID: 25716399
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
14. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
15. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
16. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome.
Sharquie KE; Al-Bayatti AA; Al-Ajeel AI; Al-Bahar AJ; Al-Nuaimy AA
Saudi Med J; 2007 Jul; 28(7):1039-43. PubMed ID: 17603706
[TBL] [Abstract][Full Text] [Related]
17. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations.
Housman E; Reynolds RV
J Am Acad Dermatol; 2014 Nov; 71(5):847.e1-847.e10; quiz 857-8. PubMed ID: 25437977
[TBL] [Abstract][Full Text] [Related]
18. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism.
Ozdemir S; Ozdemir M; Görkemli H; Kiyici A; Bodur S
Acta Obstet Gynecol Scand; 2010; 89(2):199-204. PubMed ID: 19900078
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary study on the value of ratio of serum luteinizing hormone/follicle-stimulating hormone in diagnosis of polycystic ovarian syndrome among women with polycystic ovary].
Ma CS; Lin Y; Zhang CH; Xu H; Li YF; Zhang SC; Tan Y; Quan S; Xing FQ
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):177-80. PubMed ID: 21575449
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome.
Le MT; Le VNS; Le DD; Nguyen VQH; Chen C; Cao NT
Clin Endocrinol (Oxf); 2019 Apr; 90(4):579-585. PubMed ID: 30636332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
